Transition Therapeutics Announces Participation in 12th Annual BIO CEO & Investor Conference
Transition Therapeutics Announces Participation in 12th Annual BIO CEO & Investor Conference
TORONTO, Feb. 5, 2010 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") today announced that Dr. Tony Cruz, Chairman and Chief Executive Officer, will participate on a panel entitled "Alzheimer's Disease: A Panel to Remember," at the upcoming 12th Annual BIO CEO & Investor Conference on Tuesday, February 9th, 2010 at 9:00am (Eastern time) at the Waldorf Astoria in New York.
About Transition
Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 (AZD-103) for the treatment of Alzheimer's disease and TT-223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally and developed internally using its proprietary drug discovery engine. Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the Company, please visit www.transitiontherapeutics.com.
Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC, SEC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including conducting clinical trials and potential efficacy of its products. These statements are based upon the current expectations and beliefs of Transition's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include factors beyond Transition's control and the risk factors and other cautionary statements discussed in Transition's quarterly and annual filings with the Canadian commissions.
For further information on Transition, visit www.transitiontherapeutics.com
CONTACT: Transition Therapeutics Inc.
Dr. Tony Cruz, Chief Executive Officer
416-260-7770, x.223
tcruz@transitiontherapeutics.com
Elie Farah, President & Chief Financial Officer
416-260-7770, x.203
efarah@transitiontherapeutics.com
101 College Street, Suite 220
Toronto, Ontario
M5G 1L7
Canada
